Eli Lilly and Company
LLY
$896.53
$33.673.90%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.41% | 36.83% | 36.38% | 32.00% | 27.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.41% | 36.83% | 36.38% | 32.00% | 27.41% |
| Cost of Revenue | 29.24% | 23.42% | 25.81% | 18.87% | 14.03% |
| Gross Profit | 49.23% | 40.03% | 38.99% | 35.44% | 31.04% |
| SG&A Expenses | 30.29% | 26.79% | 21.20% | 17.16% | 14.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.50% | 21.34% | 19.50% | 18.02% | 16.59% |
| Operating Income | 80.12% | 64.76% | 70.85% | 62.24% | 51.98% |
| Income Before Tax | 121.70% | 87.55% | 79.88% | 93.46% | 65.26% |
| Income Tax Expenses | 129.78% | 85.76% | 75.31% | 59.06% | 54.32% |
| Earnings from Continuing Operations | 119.98% | 87.95% | 80.93% | 102.08% | 67.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.98% | 87.95% | 80.93% | 102.08% | 67.79% |
| EBIT | 80.12% | 64.76% | 70.85% | 62.24% | 51.98% |
| EBITDA | 73.41% | 59.82% | 64.53% | 56.47% | 46.40% |
| EPS Basic | 120.64% | 88.34% | 81.01% | 102.08% | 67.85% |
| Normalized Basic EPS | 80.41% | 63.96% | 70.28% | 61.48% | 51.33% |
| EPS Diluted | 121.03% | 88.57% | 81.17% | 102.11% | 67.65% |
| Normalized Diluted EPS | 80.66% | 63.92% | 70.12% | 61.24% | 51.05% |
| Average Basic Shares Outstanding | -0.28% | -0.13% | -0.01% | 0.04% | 0.04% |
| Average Diluted Shares Outstanding | -0.40% | -0.09% | 0.07% | 0.18% | 0.18% |
| Dividend Per Share | 15.31% | 15.23% | 15.14% | 15.04% | 15.10% |
| Payout Ratio | -0.48% | -0.39% | -0.36% | -0.43% | -0.31% |